Trial reportChinese journal of integrative medicine2026
Effect and Safety of Xinfuli Granules in Chronic Heart Failure with Qi Deficiency and Blood Stasis: A Single-Center Randomized Controlled Trial.
Trial report in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical effect and safety of Xinfuli Granules (, XFLG) in improving patients with heart failure (HF) of qi deficiency and blood stasis syndrome.
methodsIn this singlecenter randomized controlled trial, HF patients were randomized (1:1) to either the XFLG group (178 cases) or the control group (178 cases). Patients in the control group received standard HF therapy. In addition, patients in the XFLG group were administered XFLG (10 g, 3 times daily) for 12 weeks. The primary outcomes observed were the composite of all-cause mortality and HF-related hospitalization; and secondary outcomes included changes in left ventricular ejection fraction (LVEF), N-terminal pro-brain natriuretic peptide (NT-pro BNP), New York Heart Association (NYHA) functional class, Minnesota Living with Heart Failure Questionnaire (MLHFQ) score, Chinese medicine (CM) syndrome score, Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7) scores.
resultsAfter 12 weeks, the XFLG group demonstrated a significantly lower incidence of the primary endpoint compared to the control group (hazard ratio, 0.566; 95% confidence interval: 0.325-0.988; P<0.05). Besides, the XFLG group showed greater improvements in LVEF and NT-pro BNP reduction (P<0.05 or P<0.01). Compared with the control group, the total effective rate of NYHA functional class and CM syndrome was significantly higher; the MLHFQ, PHQ-9, and GAD-7 scores were significantly lower in the XFLG group (P<0.05 or P<0.01).
conclusionsXFLG combined with standard HF therapy significantly reduced the risk of all-cause mortality and HF-related hospitalization composite events, improved cardiac function, and quality of life, alleviated depressive and anxiety states in HF patients, with a favorable safety profile. These results support XFLG as a promising adjunctive treatment for HF with qi deficiency and blood stasis. (Registration No. ChiCTR2100049197).
Indexed as
Identifiers
41129050What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.